LupusTrials.org This study evaluates the impact of 13 bi-weekly intravenous infusions of RSLV-132 on the cutaneous manifestations in subjects with systemic lupus erythematosus. The trial is sponsored by Resolve Therapeutics.
To Learn More Contact
James Posada, Ph.D. at 208 727 7010 or jp@resolvebio.com
ClinicalTrials.gov identifier: NCT02660944